gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · SERAHealthcareMedical Labs

Sera Prognostics, Inc. Class A Common Stock (SERA)

$2.02+4.40%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$1.93▼ 39.69% in range
Nov 3, 2025Low $1.59 · High $3.69Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Sera Prognostics closed at $2.02 on Nov 4, up 4.40%, 45.4% below its 52-week closing high. Volume of 93.6K shares was 5.18× its 20-day average (well above normal).

Split-adjusted performance: -1.7% over one month, +11.3% over six months, -37.0% over one year.

In the quarter ended Jun 30, 2026, revenue was $30K, up 76.5% from a year earlier, with a net margin of -30463.3%.

Short interest was 222.7K shares at the Oct 15 settlement, down 3.1% from the prior report (0.7% of float, 21.5 days to cover).

Market cap$79.5M39.4M shares
Revenue · quarter$30.0K+76.5% YoY
Diluted EPS$-0.18—
P/E · TTM—P/S 1,135.6×
Net margin-30,463.3%Gross -66.7%
Dividend yieldNone
52-week range1.59 – 3.69−45.4% from high
Volume93.6K5.18× 20-day avg
Volatility · 60d34.2%Annualised
Short % of float0.7%21.5 days to cover
Net cash$46.4MCash $46.4M
Next earnings—Not scheduled
Split-adjusted performance
1W −0.7%1M −1.7%3M +0.8%6M +11.3%YTD −31.7%1Y −37.0%3Y +16.5%5Y −80.7%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Medical Labs

Percentile among 24 companies (100 = best)

6-month momentum23
Revenue growth100
Net margin0
Value (low P/E)—
Size17

Industry medians: 6-month return +36.9%, revenue growth +25.0%, net margin −4.0%, P/E 32.4×.

Short interest

Details →
Shares short222.7K−3.1% vs prior
Days to cover21.5Settled Oct 15
% of float0.7%
Short vol. 10d31.8%of daily volume

Closest peers by size in Medical Labs

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
SERASera Prognostics$2.02+4.40%+11.3%+76.5%−30463.3%—$79.5M
XGNExagen$8.51+2.04%+175.4%+15.9%−16.0%—$206.2MCompare
BDSXBiodesix$21.49+2.09%+43.3%+34.2%−27.1%—$226.7MCompare
FLGTFulgent Genetics$19.68+1.60%+31.9%+4.4%−34.6%—$541.5MCompare
AMSAmerican Shared Hospital Services$1.230.00%−32.0%+19.2%−6.1%—$8.2MCompare
CSTLCastle Biosciences$35.75+1.74%+44.4%+20.1%−2.0%—$1.09BCompare
FRNMFreenome$11.30−1.48%————$1.21BCompare
LMRILumexa Imaging Holdings$13.10+16.76%+27.4%—1.0%—$1.26BCompare
ACONAclarion$1.74−1.14%−47.0%+30.5%−10899.5%—$5.0MCompare

News about Sera Prognostics

All news →

No recent articles focused on Sera Prognostics.

Quick answers

What does Sera Prognostics do?
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.
What is SERA's market cap?
$79.49M, based on the Nov 4 close of $2.02.
Does Sera Prognostics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of SERA is sold short?
222.7K shares, 0.7% of float, as of Oct 15, 2026.
What sector is SERA in?
Healthcare, in the Medical Labs industry.

About Sera Prognostics

Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.

HQ: Salt Lake City, UT72 employeesListed Jul 15, 2021seraprognostics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology